Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Balance Medical","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Continues NexoBrid\u2019s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Balance Medical

    Menu

    Balance Medical

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Balance Medical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Australia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediWound Continues NexoBrid’s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical

              Details:

              The agreement is part of MediWound's global commercialization strategy that will expand the medical and commercial potential of NexoBrid to treat skin burns.

              Lead Product(s): Bromelain

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: MediWound

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY